The anti-Candida activity of Thymbra capitata essential oil: Effect upon pre-formed biofilm

详细信息	查看全文 | 推荐本文 |

• 作者：A. Palmeira-de-Oliveira^a ; ^{apo@fcsaude.ubi.pt} ; C. Gaspar^a ; R. Palmeira-de-Oliveira^a ; A. Silva-Dias^b ; ^c ; L. Salgueiro^d ; C. Cavaleiro^d ; C. Pina-Vaz^b ; ^c ; J. Martinez-de-Oliveira^a ; ^e ; J.A. Queiroz^a ; A.G. Rodrigues^b ; ^c
• 关键词：BHI ; brain heart infusion ; CLSI ; Clinical Laboratory Standard Institute ; CV ; crystal violet ; DMSO ; dimethyl sulfoxide ; EO ; essential oil ; GC ; gas chromatography ; GC/MS ; gas chromatography/mass spectrometry ; MIC ; minimal inhibitory concentration ; MLC ; mini
• 刊名：Journal of Ethnopharmacology
• 出版年：2012
• 期刊代码：26_03788741
• 类别：pha
• 出版时间：27 March, 2012
• 卷：140
• 期：2
• 页码：379-383
• 文件大小：221 K

摘要

Ethopharmacological relevance

Thymbra capitata essential oil is traditionally considered to exhibit powerful antiseptic properties, thus being used to treat cutaneous infections. The aim of the present study was to evaluate the effect of Thymbra capitata essential oil upon pre-formed biofilm of different Candida strains while comparing it with the activity against planktonic cells.

Materials and methods

Fifteen Candida isolates were included, corresponding to clinical and collection type strains. Essential oil was obtained by hydrodistillation and its composition analysed by GC/MS. Activity upon planktonic cells was evaluated according to M27-A3 macromethod. Its effect upon 24 h preformed biofilm biomass was determined using the crystal violet procedure and the metabolic activity was studied applying the XTT/menadione technique.

Results

Biofilm biomass and metabolic activity of all tested species were reduced up to 50%at MIC values. The effect was more pronounced at double MIC values, achieving >80%reduction, except for Candida albicans that presented a more resistant profile (62%).

Conclusion

Thymbra capitata essential oil presented an important effect upon Candida biofilms. It is proposed as a valuable antifungal product to be used in an appropriate pharmaceutical formulation for the management of resistant mucocutaneous candidosis.